Tumor Markers

Cancer Antigen 15-3 (CA 15-3)

One CA 15-3 reading rarely settles anything. Built for serial monitoring, the test speaks through its trajectory, not its latest figure.

Part of the Tumor Markers — see all 11 values together, including Alpha-Fetoprotein, Beta-hCG, Cancer Antigen 125.

A single CA 15-3 number barely matters; the direction it is moving is what the test is built to read. The result behaves less like a verdict and more like a stock ticker: the price printed on any given day tells you almost nothing, while the slope of the line over weeks and months is what carries information. Cancer Antigen 15-3 is a protein shed by certain cells, reported by the lab in units per milliliter (U/mL). Most labs treat results under 30 U/mL as the reference range, though Medscape notes the exact cutoff shifts between laboratories and assays, so a 28 from one lab and a 32 from another may not mean what the gap between them suggests.

What CA 15-3 is built for is monitoring, not detection. The National Cancer Institute describes it as a tumor marker used after a breast cancer diagnosis to gauge whether treatment is working or whether disease has returned. It is not a screening test and not a diagnostic one. That distinction is the source of most of the anxiety people bring to a single result, because the number looks like it should answer "do I have cancer?" when the test was never designed to. CA 15-3 detects a different fragment of the same MUC1 antigen as CA 27-29, and the two are often followed together when monitoring a known breast cancer for response or recurrence.

Here is the fact that reframes everything. CA 15-3 is elevated in fewer than half of women with early, localized breast cancer or a small tumor, because the antigen is released mainly once tumor burden is large or has spread. Medscape places the highest readings in metastatic disease, particularly with liver or bone involvement. So a normal value rules very little out, and a high value on its own confirms nothing.

What one CA 15-3 reading can and cannot tell you

U/mL
Within the common reference range < 30

Most labs report under 30 U/mL as normal, but Medscape notes fewer than half of early or localized breast cancers raise CA 15-3 at all, so a normal number does not rule cancer out.

High-normal, watch the trend 25 to 30

A 28 sits inside the range; whether it signals anything depends on where earlier draws sat, not on the single figure.

Above the reference range > 30

A 32 may reflect a benign condition or assay variation rather than cancer; the Canadian Cancer Society stresses one level alone is not enough to act on.

The reading that actually matters Climbing across draws

Direction over time, not any single point, is what the test was built to show.

Why one number can fluctuate between draws

The Canadian Cancer Society is blunt that a single CA 15-3 level alone is not enough to judge whether treatment is working, and that serial measurements over time are what let a care team read the situation. Two draws a few weeks apart can differ for reasons that have nothing to do with the cancer. The assay carries its own variation, and several non-cancer conditions raise the marker on their own.

Benign reasons CA 15-3 can climb

  • Liver disease

    Cirrhosis and hepatitis can raise it; the Canadian Cancer Society notes CA 15-3 is cleared by the liver, so chronic liver disease, especially with ascites, pushes levels up.

  • Pregnancy and lactation

    Both can lift the marker in people without cancer.

  • Benign breast conditions

    Fibrocystic and other non-cancerous breast disease.

  • Gynecologic conditions

    Endometriosis, ovarian cysts, and pelvic inflammatory disease all appear on the Canadian Cancer Society's list of benign elevators.

MedlinePlus is explicit that benign conditions can raise tumor marker levels, and that the test cannot tell whether a marker comes from cancer or from something else. That is exactly why a high CA 15-3 with a clear scan is a common, and usually unalarming, combination. The number flagged something; the imaging clarified that it was not malignant disease.

What the trend is actually saying

This is where velocity comes in. The signal in CA 15-3 is the rate of change. A study in breast cancer surveillance found that a CA 15-3 velocity above 2.5 U/mL per year is a strong predictor of recurrence: a CA 15-3 going up steadily over successive draws, not the height of any single reading, is what flags a problem. MedlinePlus adds the mirror image, noting that a falling marker usually means treatment is helping. That is why someone watching their own labs sees a CA 15-3 that went down after chemo and reads it, correctly, as a good sign.

This is the stock-ticker logic in full. A single quote is noise. The trendline is the story.

How to read your CA 15-3 over time

  1. 1

    Ask your care team for the prior values

    A result means little without the earlier ones to compare against, because the direction is the data.

  2. 2

    Note the lab and the assay

    Since cutoffs vary between labs, comparing numbers from different assays can manufacture a change that is not real. Same lab, same method, where possible.

  3. 3

    Watch the slope, not the dot

    Clinicians track the rate of change; published surveillance work ties a velocity above 2.5 U/mL per year to recurrence risk.

  4. 4

    Bring benign explanations to the visit

    If you have liver disease, are pregnant, or are breastfeeding, tell your doctor, because these can raise the number on their own.

CA 15-3 rarely travels alone. It is usually read alongside other tumor markers, most often CEA in breast cancer follow-up, within a broader tumor markers panel, and the same trend-over-snapshot caution applies to its relatives CA 125, CA 19-9, and AFP. For a fuller picture of how these results are meant to be used, our guide to reading tumor markers walks through why a single draw is a starting point rather than an answer.

The temptation with any tumor marker is to stare at today's number. CA 15-3 rewards the opposite habit: keep the series, compare like with like, and let the trend speak.

Sources

Written and reviewed by BloodSight Editorial Team · Last updated

Try BloodSight

See your Cancer Antigen 15-3 on one timeline.

BloodSight calibrates the reference range to your sex, age, and lab — and shows every value across every visit.

Cancer Antigen 15-3 5 visits
15 U/mL −20
Mar Apr May Jun Jul

In your personal range

Normal ranges

Group Range Unit
Adult Male 0–30 U/mL
Adult Female 0–30 U/mL

Reference ranges may vary by laboratory and individual factors.

Cancer Antigen 15-3 — Common Questions

If my CA 15-3 is normal, does that rule out breast cancer?
No. Medscape notes the marker is elevated in fewer than half of women with early or localized breast cancer, because CA 15-3 is released mainly when tumor burden is large or has spread. A normal result is reassuring context, not proof, which is why the test is not used for screening or diagnosis.
Why can my CA 15-3 go up and down between draws without my cancer changing?
The assay itself has measurement variation, and several non-cancer conditions can lift the number temporarily. The Canadian Cancer Society stresses that a single level is not enough; only the pattern across repeated draws is meant to be interpreted.
What rate of increase actually matters, and is there a number?
Research in breast cancer surveillance found that a CA 15-3 velocity above 2.5 U/mL per year is a strong predictor of recurrence. The rate of change over time, rather than any one reading, is what care teams watch.
Can a high CA 15-3 mean liver disease or pregnancy instead of cancer?
Yes. The Canadian Cancer Society lists liver disease, pregnancy, lactation, benign breast conditions, endometriosis, ovarian cysts, and pelvic inflammatory disease among benign causes. MedlinePlus notes the test cannot tell whether a raised marker comes from cancer or from another condition.
Why won't my doctor use CA 15-3 to screen me even though I'm worried?
The National Cancer Institute describes CA 15-3 as a tool used after a diagnosis to monitor treatment response and recurrence. Because it misses most early cancers and rises in benign conditions, it cannot reliably find or rule out disease in someone without a diagnosis.
Why is one CA 15-3 result not enough to act on?
A single value has no direction. The Canadian Cancer Society notes that serial measurements over time are what let a care team judge whether treatment is working, so the comparison between draws carries the meaning, not the isolated figure.

Disclaimer

This content is for informational and educational purposes only. It is not intended as medical advice, diagnosis, or treatment recommendation. Reference ranges may vary by laboratory. Always discuss your results with a qualified healthcare professional.

Related Tests

Carcinoembryonic Antigen CEA

Carcinoembryonic antigen is a watch-post, not a search party. Its real job starts after a cancer is found: tracking whether the number creeps back up between scans.

→
Cancer Antigen 125 CA-125

The blood test named for cancer trips for menstruation, pregnancy and fibroids. Here is what a number over 35 actually tells you, and the screening question it can't answer.

→
Cancer Antigen 19-9 CA 19-9

CA 19-9 is the main blood marker doctors track in pancreatic and bile-duct cancers. Its strangest quirk: a sizable minority of people are simply built not to produce it at all.

→
Alpha-Fetoprotein AFP

AFP is read as a cancer marker, but a liver healing from hepatitis or cirrhosis raises it too. Here is how to read the number without panic.

→
Cancer Antigen 27-29 CA 27-29

CA 27-29 is read like a river gauge after a storm. A single waterline tells you almost nothing; whether the line is climbing or receding is the whole message.

→